Given that OC has been shown to inhibit MCL-1 [137]—a key resistance factor in venetoclax-treated MM and AML [216]—it is reasonable to anticipate potential synergism between OC and BCL-2 inhibitors such as venetoclax. This evidence concerns the gene MCL1 and acute myeloid leukemia.